• xmlui.mirage2.page-structure.header.title
    • français
    • English
  • Help
  • Login
  • Language 
    • Français
    • English
View Item 
  •   BIRD Home
  • LEDa (UMR CNRS 8007, UMR IRD 260)
  • LEDa : Publications
  • View Item
  •   BIRD Home
  • LEDa (UMR CNRS 8007, UMR IRD 260)
  • LEDa : Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browse

BIRDResearch centres & CollectionsBy Issue DateAuthorsTitlesTypeThis CollectionBy Issue DateAuthorsTitlesType

My Account

LoginRegister

Statistics

Most Popular ItemsStatistics by CountryMost Popular Authors
Thumbnail - Request a copy

Biosimilar Granulocyte Colony-Stimulating Factor Uptakes in the EU-5 Markets: A Descriptive Analysis

Bocquet, François; Paubel, Pascal; Fusier, Isabelle; Cordonnier, Anne-Laure; Le Pen, Claude; Sinègre, Martine (2014), Biosimilar Granulocyte Colony-Stimulating Factor Uptakes in the EU-5 Markets: A Descriptive Analysis, Applied Health Economics and Health Policy, 12, 3, p. 315-326. 10.1007/s40258-014-0087-8

Type
Article accepté pour publication ou publié
Date
2014
Journal name
Applied Health Economics and Health Policy
Volume
12
Number
3
Publisher
Springer
Pages
315-326
Publication identifier
10.1007/s40258-014-0087-8
Metadata
Show full item record
Author(s)
Bocquet, François
Institut Droit et Santé [IDS - U1145]
Paubel, Pascal
Institut Droit et Santé [IDS - U1145]
Fusier, Isabelle

Cordonnier, Anne-Laure

Le Pen, Claude

Sinègre, Martine
Abstract (EN)
Background Biosimilars are copies of biological reference medicines. Unlike generics (copies of chemical molecules), biologics are complex, expensive and complicated to produce. The knowledge of the factors affecting the competition following patent expiry for biologics remains limited. Objectives The aims of this study were to analyse the EU-5 Granulocyte-Colon Stimulating Factor (G-CSF) markets and to determine the factors affecting the G-CSF biosimilar uptakes, particularly that of biosimilar prices relative to originators. Methods Data on medicine volumes, values, and ex-manufacturer prices for all G-CSF categories were provided by IMS Health. Volumes were calculated in defined daily doses (DDD) and prices in Euros per DDD. In the EU-5 countries, there is 5 years of experience with biosimilar G-CSFs (2007–2011). Results Two G-CSF market profiles exist: (1) countries with a high retail market distribution, which are the largest G-CSF markets with low global G-CSF biosimilar uptakes (5.4 % in France and 8.5 % in Germany in 2011); and (2) countries with a dominant hospital channel, which are the smallest markets with higher G-CSF biosimilar uptakes (12.4 % in Spain and 20.4 % in the UK). The more the decisions are decentralized, the more their uptakes are high. The price difference between G-CSF biosimilars and their reference plays a marginal role at a global level (price differences of +13.3 % in the UK and −20.4 % in France). Conclusion The competition with G-CSF biosimilars varies significantly between EU-5 countries, probably because of G-CSF distribution channel differences. Currently, this competition is not mainly based on prices, but on local political options to stimulate tendering between them and recently branded second- or third-generation products.
Subjects / Keywords
Health Economics; Pharmacoeconomics and Health Outcomes; Public Health; Quality of Life Research
JEL
I31 - General Welfare, Well-Being
I18 - Government Policy; Regulation; Public Health
I12 - Health Behavior

Related items

Showing items related by title and author.

  • Thumbnail
    A Long War Begins: Biosimilars Versus Patented Biologics – A Retrospective Analysis Of The Eu-5 And Japanese Erythropoetins Markets 
    Bocquet, François; Paubel, Pascal; Fusier, Isabelle; Cordonnier, Anne-Laure; Le Pen, Claude; Sinègre, Martine (2014) Article accepté pour publication ou publié
  • Thumbnail
    To What Extent Can Biosimilars Compete with Brand Name Biologics? A EU-5 Granulocyte-Colony Stimulating Factors Markets Analysis 
    Fusier, Isabelle; Cordonnier, Anne-Laure; Paubel, Pascal; Bocquet, François; Le Pen, Claude (2013) Article accepté pour publication ou publié
  • Thumbnail
    Biosimilar Versus Patented Erythropoietins: Learning from 5 Years of European and Japanese Experience 
    Bocquet, François; Paubel, Pascal; Fusier, Isabelle; Cordonnier, Anne-Laure; Sinègre, Martine; Le Pen, Claude (2015) Article accepté pour publication ou publié
  • Thumbnail
    Temporary Authorization for Use: Does the French Patient Access Programme for Unlicensed Medicines Impact Market Access After Formal Licensing? 
    Degrassat-Théas, Albane; Paubel, Pascal; Parent de Curzon, Olivier; Le Pen, Claude; Sinègre, Martine (2013) Article accepté pour publication ou publié
  • Thumbnail
    Temporary use authorizations : the economic and clinical future of drugs used in the french compassionate program 
    Le Pen, Claude; Parent de Curzon, Olivier; Paubel, Pascal; Sinègre, Martine; Degrassat-Théas, Albane (2011) Article accepté pour publication ou publié
Dauphine PSL Bibliothèque logo
Place du Maréchal de Lattre de Tassigny 75775 Paris Cedex 16
Phone: 01 44 05 40 94
Contact
Dauphine PSL logoEQUIS logoCreative Commons logo